RDIF announces launch of free medical consultations via Doctis online service for VTB customers
Moscow, April 3, 2020 - The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, VTB and MD Medical Group announce the launch of free online medical consultations for VTB customers and their families through the Doctis telemedicine service, an RDIF portfolio company.
Via the Doctis mobile application, a general practitioner, pediatrician and infectiologist on duty will respond to questions related to the symptoms of the coronaviral infection and necessary precautionary measures.. The “Medical adviser” service will help arrange examination and treatment at a specialized medical centre, reporting the nearest clinics and laboratories where COVID-19 tests can be taken. In addition, via the Doctis app, a general practitioner and pediatrician will be able to provide assistance in general health issues that do not require emergency medical aid.
Doctors of MD Medical Group, United Medical Systems and other leading specialized medical centers will provide consultations in the form of a text chat, an audio or video call.
In 2018, RDIF in collaboration the Russian-Japanese Investment Fund and a number of Middle Eastern partners invested in the Doctis multifunctional telemedicine service. The investment was aimed at scaling up and implementing technological solutions in the AI field, as well as improving the proprietary mobile app and developing the first fully virtual clinic in Russia.
Anatoly Braverman, First Deputy CEO of the Russian Direct Investment Fund, said:
“RDIF has been actively involved in the fight against the spread of COVID-2019 since the first news of the novel coronavirus. In the conditions of the pandemic and the quarantine, it is necessary to provide the opportunity to as many people in any region of the country as possible to receive consultations from professional and reputable doctors remotely. Therefore, in the current situation, we have decided to reinvest the dividends from Doctis in the fight against coronavirus. RDIF and VTB Bank are delighted to make the Doctis service available for a larger number of Russian citizens.”
Anatoly Pechatnikov, Deputy President and Chairman of VTB Bank Management Board, noted:
“Customer care is the highest value of VTB Bank. In the current environment, we have made several important decisions that will help our borrowers to facilitate the implementation of their financial obligations. One of these decisions is the introduction of credit holidays with deferred payment for customers affected by the coronavirus pandemic. We understand that health issues are now the most relevant for our customers, so we are pleased to offer them free access to quality online medicine. The new service will enable them to receive all the necessary consultations in a timely manner, without leaving home."
Mark Kurtser, founder of Doctis, CEO of MD Medical Group, noted:
“It is now very important to avoid unnecessary visits to public venues, including clinics, unless in an emergency. Many issues can be resolved through a so-called telemedicine consultation – remotely, via a mobile device. We are proud that VTB has selected for its customers our service, which involves leading doctors who will provide the necessary assistance remotely and in a timely manner.”
Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling more than RUB1.7 tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6% of Russia’s GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 15 countries that total more than $40 bn.
RDIF takes steps to counteract COVID-19:
- Jointly with Japan’s K.K. Mirai Genomics, RDIF has invested in the production and distribution of the Russian-Japanese diagnostic system EMG - Evotech-Mirai Genomics, the world’s most highly accurate and high-speed line of systems for the detection of coronavirus. It allows to receive results in 30 minutes. A range of testing systems has been adapted for using in both fixed laboratories and unique portable mini-laboratories (the size of a small suitcase) and can be used anywhere, including hospitals and public institutions such as schools, offices, airports and train stations. The system has been approved by the Federal Service for Surveillance in Healthcare (Roszdravnadzor) for use in the Russian Federation;
- Jointly with the ChemRar Group, RDIF is launching the production of Favipiravir, a drug that has proven effective in the treatment of infected patients in China;
- RDIF was one of the initiators of the Alliance against coronavirus, which also included the Russian Union of Industrialists and Entrepreneurs (RUIE), Yandex, Mail.ru Group and the Rossiya Segodnya international news agency;
- Alongside Rossiya Segodnya, RDIF has published a unique “Handbook of COVID-19 Prevention and Treatment”, based on China’s experience in the fight against coronavirus. The Handbook is available at: https://rdif.ru/data/file/COVID_19_Book.pdf
Further information can be found at rdif.ru
Doctis is a multifunctional healthcare online platform. It operates an online medical centre that allows patients to comprehensively evaluate and track their health. It partners with the state and private clinics and experts to provide services based on user's personal medical data, utilising a single online medical data storage system, which includes medical records of all family members. www.doctis.ru.
For additional information contact:
Russian Direct Investment Fund
Tel: +7 495 644 34 14, ext. 2395
Mobile: +7 916 110 31 41
Andrew Leach / Maria Shiryaevskaya
Tel: +44 (0) 20 7796 4133